TY - JOUR
T1 - Metrics other than potency reveal systematic variation in responses to cancer drugs
AU - Fallahi-Sichani, Mohammad
AU - Honarnejad, Saman
AU - Heiser, Laura M.
AU - Gray, Joe W.
AU - Sorger, Peter K.
N1 - Funding Information:
We thank W. Chen, G. Berriz, M. Niepel, M. Hafner, D. Flusberg, T. Mitchison, D. Marks and C. Shamu for help. This work was supported by the US National Institutes of Health–Library of Integrated Network-Based Cellular Signatures Program grant HG006097 to P.K.S. and by Stand Up to Cancer grant AACR-SU2C-DT0409 to P.K.S. and J.W.G. M.F.-S. is supported by a Merck Fellowship of the Life Sciences Research Foundation.
PY - 2013/11
Y1 - 2013/11
N2 - Large-scale analysis of cellular response to anticancer drugs typically focuses on variation in potency (half-maximum inhibitory concentration, (IC 50)), assuming that it is the most important difference between effective and ineffective drugs or sensitive and resistant cells. We took a multiparametric approach involving analysis of the slope of the dose-response curve, the area under the curve and the maximum effect (E max). We found that some of these parameters vary systematically with cell line and others with drug class. For cell-cycle inhibitors, E max often but not always correlated with cell proliferation rate. For drugs targeting the Akt/PI3K/mTOR pathway, dose-response curves were unusually shallow. Classical pharmacology has no ready explanation for this phenomenon, but single-cell analysis showed that it correlated with significant and heritable cell-to-cell variability in the extent of target inhibition. We conclude that parameters other than potency should be considered in the comparative analysis of drug response, particularly at clinically relevant concentrations near and above the IC 50.
AB - Large-scale analysis of cellular response to anticancer drugs typically focuses on variation in potency (half-maximum inhibitory concentration, (IC 50)), assuming that it is the most important difference between effective and ineffective drugs or sensitive and resistant cells. We took a multiparametric approach involving analysis of the slope of the dose-response curve, the area under the curve and the maximum effect (E max). We found that some of these parameters vary systematically with cell line and others with drug class. For cell-cycle inhibitors, E max often but not always correlated with cell proliferation rate. For drugs targeting the Akt/PI3K/mTOR pathway, dose-response curves were unusually shallow. Classical pharmacology has no ready explanation for this phenomenon, but single-cell analysis showed that it correlated with significant and heritable cell-to-cell variability in the extent of target inhibition. We conclude that parameters other than potency should be considered in the comparative analysis of drug response, particularly at clinically relevant concentrations near and above the IC 50.
UR - http://www.scopus.com/inward/record.url?scp=84886509950&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886509950&partnerID=8YFLogxK
U2 - 10.1038/nchembio.1337
DO - 10.1038/nchembio.1337
M3 - Article
C2 - 24013279
AN - SCOPUS:84886509950
SN - 1552-4450
VL - 9
SP - 708
EP - 714
JO - Nature Chemical Biology
JF - Nature Chemical Biology
IS - 11
ER -